A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Clinical trial NCT00378482 · COMPLETED

Trial details

NCT number: NCT00378482
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Neoplasms Melanoma Prostatic Neoplasms Renal Cell Carcinoma Neoplasms Patients Who Have/Have Had Melanoma and Other Tumors

Start date: 2007-03-05
Primary completion: 2023-10-27
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.